Preda L, Alberoni M, Bressi S, Cattaneo C, Parini J, Canal N, Franceschi M
Department of Neurology, University of Milan, San Raffaele Hospital, Italy.
Psychopharmacology (Berl). 1993;110(4):421-6. doi: 10.1007/BF02244648.
The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans.
东莨菪碱致遗忘模型已用于测试12名健康志愿者中奥拉西坦的药效学功效。根据双盲交叉不完全随机区组设计，将受试者分为四个实验组。在进行基线神经心理学检查后，每位受试者在两个单独的时间段接受以下治疗之一作为急性口服剂量：奥拉西坦800、1600、2400毫克或安慰剂。治疗1小时后，皮下注射氢溴酸东莨菪碱（0.5毫克）。在给予东莨菪碱之前以及之后1、2、3和25小时对认知表现进行测试。东莨菪碱导致言语情景记忆、语义记忆和注意力测试的表现恶化。与安慰剂相比，奥拉西坦改善了总体测试表现，在1600毫克剂量时对单词列表的延迟回忆有统计学显著差异，并且在语义记忆和注意力方面也显示出与剂量相关的对东莨菪碱诱导效应的拮抗作用。急性剂量的奥拉西坦在减轻东莨菪碱诱导的认知障碍方面的功效支持了这种遗忘药理学模型在研究认知增强剂对人类影响方面的潜在有用性。
